%0 Journal Article
%T Addition of Capecitabine in Breast Cancer First-line Chemotherapy Improves Survival of Breast Cancer Patients
%A Di Xu
%A Jinhai Tang
%A Li Ding
%A Wei Zhang
%A Wenjuan Tang
%A Xingjiang Li
%A Xiu Chen
%A Zhixiang Mao
%J Journal of Cancer
%D 2019
%I Ivyspring International Publisher
%R 10.7150/jca.29739
%X Objective: Capecitabine is an antimetabolic fluoropyrimidine deoxynucleoside carbamate drug that can be converted to 5-FU in vivo. Currently, the role of capecitabine in the treatment of advanced breast cancer has been recognized. Also, Several meta-analyses have elucidated the role of capecitabine in the treatment of breast cancer, indicating that taxane-based regimen with capecitabine may be an effective, convenient, and well tolerated regimen in patients with early breast cancer. However, the correlation between capecitabine-based combination first-line chemotherapy and breast cancer survival remains unclear. Here, we present a meta-analysis to systematically evaluate the safety and effectiveness of capecitabine-based combination with first-line chemotherapy treatment in breast cancer.
%K breast cancer
%K capecitabine
%K disease-free survival (DFS)
%K overall survival (OS)
%U http://www.jcancer.org/v10p0418.htm